Skip to content

Oncopeptides announces the Nomination Committee

Stockholm – October 20, 2023 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers today announces that the composition of the Nomination Committee has been established.

According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2024 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2023 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.
The Nomination Committee in respect of the annual general meeting 2024 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September 2023.

  • Staffan Lindstrand, appointed by HealthCap VI L.P.
  • Patrik Sobocki, appointed by Stiftelsen Industrifonden
  • Caroline Mebius, appointed by Handelsbanken funds
  • Per Wold-Olsen, the Chairman of the Board

The Nomination Committee’s proposals will be presented in the Notice to the annual general meeting 2024 and on Oncopeptides’ website,
Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to (subject “Nomination Committee”) or by letter posted to Oncopeptides AB (publ), Attn: Oncopeptides Nomination Committee, Luntmakargatan 46, SE-111 37 Stockholm, Sweden.
A proposal must reach the nomination committee no later than by April 3, 2024, to be included in the notice to attend and the agenda for the annual general meeting.

For more information, please contact:
David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)
Cell phone: +46 76 229 38 68

About Oncopeptides
Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. 

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see:

Oncopeptides announces the Nomination Committee

Source: Oncopeptides